☆ 4.8 Editorial Material

Liquid Biopsy for Precision Adjuvant Chemotherapy in Colon Cancer

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie et al.

Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Aparna R. Parikh et al.

Summary: The study demonstrates that detection of persistent circulating tumor DNA in plasma shows favorable sensitivity and specificity for predicting recurrence after curative-intent surgery for colorectal cancer. Integrating analysis of genomic and epigenomic signatures enhances the accuracy of detection, supporting the potential clinical utility of plasma-only ctDNA minimal residual disease detection.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

Julien Taieb et al.

Summary: The study showed that ctDNA presence in patients with stage III colon cancer is associated with disease prognosis, with different prognostic value observed in certain subgroups.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology